The Cow Milk Symptom Score (CoMiSS (TM)) in presumed healthy infants

Fecha de publicación:

Autores de IIS La Fe

Participantes ajenos a IIS La Fe

  • Vandenplas, Y
  • Salvatore, S
  • Carvajal, E
  • Szajewska, H
  • Huysentruyt, K

Grupos

Abstract

Objective The Cow's Milk-related Symptom Score (CoMiSS (TM)) was developed as an awareness tool to recognize possible manifestations of cow's milk protein allergy (CMPA). Arbitrarily, a cutoff value of >= 12 was defined as a "positive score." The aim of this study was to determine an age-related CoMiSS in healthy infants to minimize the risk of false reassurance or over-diagnosis of CMPA in case of a negative or positive score, respectively. Methods General pediatricians determined the CoMiSS in presumed healthy infants aged <= 6 months during a routine visit. Exclusion criteria included any known acute or chronic disease, preterm delivery (< 37 weeks), therapeutic formula, any food supplement (except vitamins) or medication. Results Data from 891 consecutive infants were collected. Complete information was obtained from only 413 (46.4%) infants: Belgium: 31.2%, Italy 18.2%, Poland 19.1% and Spain 31.5%. Since gender (girls vs boys) (p = 0.579) had no influence on the CoMiSS, the data were recalculated to include those infants with missing gender. The overall median and mean (SD) CoMiSS scores were, respectively, 3.0 and 3.7 (2.9). The 95th percentile was 9. Median crying (p<0.001), regurgitation (p = 0.009) and eczema (p = 0.039) scores differed significantly across the age categories. The other components of the CoMiSS were not age dependent. Conclusion In healthy infants <= 6 months, the median CoMiSS is 3.0. More prospective studies in different sites and comparing healthy and allergic infants are warranted to obtain further evidence on the utility of the CoMiSS.

Datos de la publicación

ISSN/ISSNe:
1932-6203, 1932-6203

Plos One  PUBLIC LIBRARY SCIENCE

Tipo:
Article
Páginas:
-
Factor de Impacto:
1,100 SCImago
Cuartil:
Q1 SCImago

Citas Recibidas en Web of Science: 21

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • ALLERGY; CHILDREN; REGURGITATION; PREVALENCE; FORMULA; GROWTH

Campos de estudio

Proyectos asociados

ANALISIS DE NUEVOS GENES IMPLICADOS EN LA PATOGENESIS DE LA ENFERMEDAD CELIACA

Investigador Principal: CARMEN RIBES KONINCKX

PI02/0573 . INSTITUTO DE SALUD CARLOS III . 2004

INNOVATIVE APPROACH FOR SELF-MANAGEMENT AND SOCIAL WELFARE OF CYSTIC FIBROSIS PATIENTS IN EUROPE: DEVELOPMENT, VALIDATION AND IMPLEMENTATION OF A TELEMATICS TOOL. MyCyFAPP

Investigador Principal: CARMEN RIBES KONINCKX

643806_H2020-PHC-2014-single-stage-MyCyFApp . COMISION EUROPEA . 2015

NUEVA ESTRATEGIA PARA LA DERIVACIÓN DE HEPATOCITOS FUNCIONALES DE MUJERES AFECTAS DE DEFICIENCIA DE ORNITINA TRANSCARBAMILASA

Investigador Principal: BERNARDO ROQUE BORT MARTÍ

SAF2014-51991-R . MINISTERIO DE ECONOMIA Y COMPETITIVIDAD . 2015

UN REGISTRO NO INTERVENCIONISTA A LARGO PLAZO PARA EVALUAR LA SEGURIDAD Y EFECTIVIDAD DE HUMIRA® (ADALIMUMAB) EN PACIENTES PEDIÁTRICOS CON ENFERMEDAD DE CROHN (EDC) ACTIVA ENTRE MODERADA Y GRAVE (CAPE).

Investigador Principal: ESTHER DONAT ALIAGA

P11-292 . 2015

ESTUDIO ABIERTO, MULTICÉNTRICO PARA EVALUAR LA FARMACOCINÉTICA, LA SEGURIDAD Y LA EFICACIA DE OMBITASVIR (OBV), PARITAPREVIR (PTV), RITONAVIR (RTV), CON O SIN DASABUVIR (DSV) Y CON O SIN RIBAVIRINA (RBV) EN PACIENTES PEDIÁTRICOS CON INFECCIÓN CRÓNICA POR EL VIRUS DE LA HEPATITIS C (VHC) GENOTIPO 1 O 4 (ZIRCON).

Investigador Principal: CARMEN RIBES KONINCKX

M14-748 . 2016

IMPACT ASSESSMENT THROUGH A EUROPEAN MULTICENTRE CLINICAL TRIAL: VALIDATION OF MYCYFAPP AS A PORTABLE SYSTEM FOR SELF-MANAGEMENT IN CHILDREN WITH CF.

Investigador Principal: CARMEN RIBES KONINCKX

MYCYFAPP . 2018

ESTUDIO ABIERTO Y MULTICÉNTRICO PARA EVALUAR LA FARMACOCINÉTICA, LA SEGURIDAD Y LA EFICACIA DE GLECAPREVIR/PIBRENTASVIR EN PACIENTES PEDIÁTRICOS CON INFECCIÓN CRÓNICA POR EL VIRUS DE LA HEPATITIS C (VHC) DE GENOTIPO 1-6.

Investigador Principal: CARMEN RIBES KONINCKX

M16-123 . 2017

ESTUDIO DE SEGURIDAD Y CAPACIDAD NUTRICIONAL DE UNA NUEVA FORMULA HIPOALERGICA PARA LACTANTES CON DIVERSAS FORMAS DE ALERGIA A LAS PROTEINAS DE LA LECHE DE VACA.

Investigador Principal: CARMEN RIBES KONINCKX

HER-FHT-2009-01 . 2010

A MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED, DOUBLE-BLIND STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF LUBIPROSTONE IN PAEDIATRIC SUBJECTS AGED >= 6 YEARS TO < 18 YEARS WITH FUNCTIONAL CONSTIPATION. / ESTUDIO MULTICENTRICO, ALEATORIZADO, CONTR OLADO CON PLACEBO Y CON DOBLE ANONIMATO (DOBLE CIEGO) DE LA EFICACIA, SEGURIDAD Y FARMACOCINETICA DE LA LUBIPROSTONA EN PACIENTES PEDIATRICOS CON EDAD . 6 ANOS Y < 18 ANOS CON ESTRENIMIENTO FUNCIONAL.

Investigador Principal: CARMEN RIBES KONINCKX

SAG/0211PFC-1131

A MULTICENTRE, LONG-TERM SAFETY, EFFICACY AND PHARMACOKINETICS STUDY OF LUBIPROSTONE IN PAEDIATRIC SUBJECTS AGED >= 6 TO <18 YEARS WITH FUNCTIONAL CONSTIPATION./ ESTUDIO MULTICÉNTRICO A LARGO PLAZO SOBRE LA SEGURIDAD, LA EFICACIA Y LA FARMACOCINÉTICA DE L UBIPROSTONA EN PACIENTES PEDIÁTRICOS DE EDADES COMPRENDIDAS ENTRE >= 6 AÑOS Y < 18 AÑOS CON ESTREÑIMIENTO FUNCIONAL.

Investigador Principal: CARMEN RIBES KONINCKX

SAG/0211PFC-11S1 . 2015

ESTUDIO FARMACOEPIDEMIOLÓGICO PARA ESTABLECER EL PERFIL DE SEGURIDAD A LARGO PLAZO DE TENOFOVIR DISOPROXIL FUMARATO (TENOFOVIR DF, VIREAD®) Y DESCRIBIR EL TRATAMIENTO DE LA TOXICIDAD RENAL Y ÓSEA ASOCIADA A TENOFOVIR DF EN ADOLESCENTES DE 12 A <18 AÑOS CO N HEPATITIS B CRÓNICA (HBC) EN EUROPA.

Investigador Principal: CARMEN RIBES KONINCKX

GS-EU-174-1403 . 2015

Cita

Compartir